The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.
The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.
The partners will utilize Clearbridge's microfluidics-based rare cell separation technology, with the goal of potentially creating a new product line.
The agreement allows Sysmex to distribute two Streck blood collection tubes for cell-free DNA as part of its medical diagnostics products and services.
The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.
Sysmex's cell-free tumor DNA analysis technology will be used in oncology clinical trials supported by Covance Drug Development, a LabCorp subsidiary.
IndivuTest will offer the Sysmex Inostics OncoBEAM test in Germany, Austria, and Switzerland under an exclusive distribution agreement.
Vall d'Hebron's Institute of Oncology will use the liquid biopsy-based OncoBEAM RAS test to research precision medicine approaches for metastatic colorectal cancer patients.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.